Skip to main content

Table 2 Subgroup analysis of overall mortality with tigecycline versus other antibiotics for treatment of bloodstram infections in controlled studies

From: The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis

Variables

Studies, no. (patients, no.)

Mortality of tigecycline compared with control OR (95% CI); P

Heterogeneity of studies

Monotherapy vs combination

6 (250)

2.733 (1.533–4.873); 0.001

X2 = 5.47, df = 5, (P = 0.361), I2 = 8.7%

Tigecycline plus polymyxins based vs other antibiotics combination

5 (289)

0.680 (0.407–1.135); 0.140

X2 = 2.88, df = 4, (P = 0.578), I2 = 0.0%

Kp BSI

6 (466)

0.678 (0.457–1.006); 0.054

X2 = 3.95, df = 5, (P = 0.556), I2 = 0.0%

KPC-Kp BSI

5 (398)

0.636 (0.417–0.971); 0.036

X2 = 3.31, df = 4, (P = 0.507), I2 = 0.0%

Acinetobacter BSI

3 (221)

0.967 (0.096–9.759); 0.978

X2 = 23.76, df = 2, (P = 0.001), I2 = 91.6%

  1. CI, confidence interval; OR, odds ratio